Expression of Epidermal Growth Factor Receptor in Normal Ovary and in Ovarian Tumors

Stewart, Colin J.R.; Owens, OJ; Richmond, James; McNicol, A. M.

doi:10.1097/00004347-199210000-00004

Cited by 20 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With respect to histology, in agreement with what others have reported [20,[29][30][31][32]] no significant association between EGFR status and subtypes of ovarian carcinoma was demonstrated, and only a trend towards a smaller percentage of reactive cases in undifferentiated carcinomas was observed. In our study, however, this subgroup of cancer was relatively small.…”

Section: Discussionsupporting

confidence: 92%

See 1 more Smart Citation

Epidermal Growth Factor Receptor and c-erbB-2 Oncoproteins in Tissue and Tumor Effusion Cells of Histopathologically Different Ovarian Neoplasms

Harłozińska

Bär²,

Sobańska³

et al. 1998

Tumor Biol

View full text Add to dashboard Cite

The overexpression of two growth factor receptors – epidermal growth factor receptor (EGFR) and c-erbB-2 – was evaluated immunohistochemically in malignant and benign ovarian neoplasms, considering the stage of the disease and histology of tumors. The comparison of EGFR and c-erbB-2 reactivity in tissue sections and respective cyst and/or ascitic fluid cells was also performed. c-erbB-2 expression was detected in 44.4% of ovarian carcinomas, and in benign neoplasms there was no evidence of its staining, while EGFR reactivity was found both in malignant (58.7%) and benign (50%) tumors. Significant heterogeneity of staining was observed, however, the relationship between EGFR and c-erbB-2 expression in tissue sections and cyst and/or ascitic fluid cells in individual patients was evident. The expression of both growth factor receptors was not correlated with histopathological subtypes of ovarian neoplasms. The c-erbB-2 oncoprotein was detected more frequently in III/IV than in I/II stages according to the criteria of the International Federation of Gynecology and Obstetrics (FIGO) and the EGFR expression was independent of the clinical advancement of the disease. The coexpression of c-erbB-2 and EGFR was shown in 32% of ovarian carcinomas, and it dominated in cases with FIGO stages III/IV. Our results indicate that the increase of the EGFR expression appears to be associated with early stages of ovarian tumorigenesis, and the enhancement of c-erbB-2 reactivity may cooperate with EGFR activation in the development and progression of ovarian carcinomas.

show abstract

Section: Discussionsupporting

confidence: 92%

“…This incidence is comparable to that indicated in the majority of reports [14,20,29]. Some authors, however, using different antibodies have found EGFR staining in a very low (12-20%) [10,13] or very high (75-100%) [12,30] percentage of common epithelial ovarian carcinomas.…”

Section: Discussionsupporting

confidence: 87%

Epidermal Growth Factor Receptor and c-erbB-2 Oncoproteins in Tissue and Tumor Effusion Cells of Histopathologically Different Ovarian Neoplasms

Harłozińska

Bär²,

Sobańska³

et al. 1998

Tumor Biol

View full text Add to dashboard Cite

show abstract

“…Ovarian tumors are pathologically heterogeneous, and although the initiating events in ovarian tumor development are poorly understood, ovarian tumorigenesis is characterized by multiple genetic alterations and molecular signatures (2). The epidermal growth factor (EGF) receptor (EGFR) is overexpressed or mutated in a wide variety of human tumors including ovarian carcinomas (3)(4)(5)(6)(7)(8). Cellular responses to EGFR activation include those that play a critical role in tumor growth, survival, and progression, whereas EGFR overexpression in tumors has been associated clinically with progression and metastasis (9)(10)(11).…”

Section: Introductionmentioning

confidence: 99%

PEA3 Is Necessary for Optimal Epidermal Growth Factor Receptor–Stimulated Matrix Metalloproteinase Expression and Invasion of Ovarian Tumor Cells

Dahl

Zeineldin

Hudson

2007

Molecular Cancer Research

View full text Add to dashboard Cite

Elevated expression of the epidermal growth factor (EGF) receptor (EGFR) is detected in human ovarian tumors and is associated with decreased recurrence-free and overall survival. EGFR activation affects tumor progression in part by promoting tumor invasion through the induction of prometastatic matrix metalloproteinases (MMP). PEA3, an ETS family transcription factor, is elevated in advanced and metastatic ovarian cancer and regulates MMPs in various cell types, therefore, we investigated whether PEA3 is required for the EGFR-dependent induction of MMP mRNA. MMP-9 and MMP-14 mRNA levels were selectively increased in response to EGFR activity in ovarian tumor cells. EGFR activation resulted in nuclear accumulation of PEA3 and direct binding of PEA3, but not the related protein ETS-1, to the endogenous MMP-9 and MMP-14 promoters. Furthermore, PEA3 overexpression was sufficient to induce MMP-9 and MMP-14 mRNA, tumor cell migration, and invasion, suggesting that PEA3 is an important contributor to the metastatic phenotype. Additionally, inhibition of PEA3 expression via short interfering RNA reduced the EGF induction of MMP-9 and MMP-14 gene expression by 92% and 50%, respectively, and impaired EGF-stimulated tumor cell invasion. These results suggest that PEA3 is regulated by EGFR and that the elevated PEA3 expression detected in human ovarian cancer may divert cells to a more invasive phenotype by regulating MMP-9 and MMP-14. (Mol Cancer Res 2007;5(5):413 -21)

show abstract

“…At present, although EGFR expression has been widely demonstrated in ovarian cancer (Bauknecht et al, 1988;Battaglia et al, 1989;Berchuck et al, 1991;Stewart et al, 1992;van der Burg et al, 1993), few studies have investigated the prognostic significance of EGFR (Bauknecht et al, 1988;Berchuck et al, 1991;van der Burg et al, 1993). Some evidence does, however, demonstrate that high EGFR levels may be a negative prognostic indicator in many tumour types (Sainsbury et al, 1987;Neal et al, 1991;Maurizi et al, 1992;Scambia et al, 1994).…”

mentioning

confidence: 99%

Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy

Scambia

Benedetti‐Panici²,

Ferrandina³

et al. 1995

Br J Cancer

View full text Add to dashboard Cite

Summary The expression of epidermal growth factor receptor (EGFR), oestrogen receptor (ER) and progesterone receptor (PR) was assayed by a radioreceptor method in 117 primary ovarian cancers. EGFR was not significantly related to any of the clinicopathological parameters examined. In patients with stage II-IV disease who underwent second-look surgery after primary chemotherapy, a significant correlation between high EGFR levels and poor response to chemotherapy was demonstrated (P = 0.031). Moreover, post-operative residual tumour showed an independent role in predicting chemotherapy response (P = 0.0007) and EGFR status showed a borderline significance (P = 0.052) in the multivariate analysis. No correlation between steroid hormone receptors and clinicopathological parameters was observed. Whereas a significant relationship was shown between EGFR positivity and a shorter overall survival (OS) (P = 0.0022) and progression-free survival (PFS) (P = Neal et al., 1991;Maurizi et al., 1992; Scambia et al., 1994). Moreover, in breast cancer EGFR expression seems to be a feature of hormone-independent aggressive clinical behaviour (Klijn et al., 1992). Our previous study The membrane fraction and cytosol were prepared as described elsewhere . Briefly, tumour specimens were finely minced and homogenised in five volumes of ice-cold buffer consisting of 25 mM Tris, 1.5 mM EDTA, 5 mM sodium azide, 20% glycerol (TENG) plus 0.1 % monothioglycerol, by applying several intermittent bursts of an Ultra-Turrax homogeniser. The crude homogenate was centrifuged at 7000 g for 20 min at 0°C in order to separate nuclear fraction from the cytosol fraction. The supernatants were then centrifuged at 105 000 g for 75 min at 0°C, obtaining the membrane pellet and the cytosolic fraction.

show abstract

Expression of Epidermal Growth Factor Receptor in Normal Ovary and in Ovarian Tumors

Cited by 20 publications

References 0 publications

Epidermal Growth Factor Receptor and c-erbB-2 Oncoproteins in Tissue and Tumor Effusion Cells of Histopathologically Different Ovarian Neoplasms

Epidermal Growth Factor Receptor and c-erbB-2 Oncoproteins in Tissue and Tumor Effusion Cells of Histopathologically Different Ovarian Neoplasms

PEA3 Is Necessary for Optimal Epidermal Growth Factor Receptor–Stimulated Matrix Metalloproteinase Expression and Invasion of Ovarian Tumor Cells

Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy

Contact Info

Product

Resources

About